tbuckley/cabot-search huggingface dataset:
Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression
Authors: Ekta Khattar, Pavanish Kumar, Chia Yi Liu, Semih Can Akıncılar, Anandhkumar Raju, Manikandan Lakshmanan, Julien Jean Pierre Maury, Yu Qiang, Shang Li, Ern Yu Tan, Kam M. Hui, Ming Shi, Yuin Han Loh, Vinay Tergaonkar
Journal: Journal of Clinical Investigation (2016)

Transcriptional reactivation of telomerase reverse transcriptase (TERT) reconstitutes telomerase activity in the majority of human cancers. Here, we found that ectopic TERT expression increases cell proliferation, while acute reductions in TERT levels lead to a dramatic loss of proliferation without any change in telomere length, suggesting that the effects of TERT could be telomere independent. We observed that TERT determines the growth rate of cancer cells by directly regulating global protein synthesis independently of its catalytic activity. Genome-wide TERT binding across 5 cancer cell lines and 2 embryonic stem cell lines revealed that endogenous TERT, driven by mutant promoters or oncogenes, directly associates with the RNA polymerase III (pol III) subunit RPC32 and enhances its recruitment to chromatin, resulting in increased RNA pol III occupancy and tRNA expression in cancers. TERT-deficient mice displayed marked delays in polyomavirus middle T oncogene-induced (PyMT-induced) mammary tumorigenesis, increased survival, and reductions in tRNA levels. Ectopic expression of either RPC32 or TERT restored tRNA levels and proliferation defects in TERT-depleted cells. Finally, we determined that levels of TERT and tRNA correlated in breast and liver cancer samples. Together, these data suggest the existence of a unifying mechanism by which TERT enhances translation in cells to regulate cancer cell proliferation.
P2-078: Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients
Authors: Hyun Woo Lee, Jae Ho Han, Jang Hee Kim, Myoung Hee Lee, Seok Yun Kang, Jin-Hyuk Choi, Young Taek Oh, Gwang Joo Park, Seong Chul Hwang, Seung Soo Sheen, Ho-Yeong Lim
Journal: Journal of Thoracic Oncology (2007)
Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions.
Authors: P. Dileo, R. Sanfilippo, F. Grosso, E. Fumagalli, J. Blay, J. Domont, A. Le Cesne, J. C. Tercero, P. G. Casali
Journal: Journal of Clinical Oncology (2010)

10030 Background: T is effective in advanced soft tissue sarcomas, with special regard to liposarcoma and leiomyosarcoma. Mechanisms of action may be multifold: induction of DNA damage, involving specific and peculiar DNA repair pathways, and transcriptional interference. The latter mechanism may be more significant in myxoid liposarcomas. Other translocation-related sarcomas may be sensitive to T. SS is a translocation-related sarcoma. We report on a series of 39 pts with advanced SS who were treated with T in three European sarcoma centres within compassionate-use programs. Methods: The datasets of Istituto Nazionale Tumori, Milano, Italy; Centre Leon Berard, Lyon, and Institut Gustave Roussy, Villejuif, France, were retrospectively reviewed from 2000 to 2009. Overall, 21/39 pts were female, and age ranged from 18 to 67 years. Sites of primary lesions were extremities = 23, mediastinum = 6, trunk = 5, pelvis = 4, head and neck = 1. At the time of treatment, all pts presented with metastatic disease, and were pre-treated with a median of 3 chemotherapy lines (range: 2-7). Results: 186 courses were delivered (median: 3). All pts were evaluable for response. Seven pts had a PR, for an overall response rate (RR) of 18%. In addition, 2 MR, and 11 SD were observed. Progression-free survival at 6 months (PFR-6) was 23%. Median PFS was 29, 21, and 18 weeks, respectively, in pts who experienced PR, MR and SD. Conclusions: In this series of adult pts with advanced pre-treated SS, T induced a RR of 18% and a PFR-6 of 23%. This suggests that SS constitute a sarcoma subgroup with distinct sensitivity to T. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration PharmaMar PharmaMar PharmaMar PharmaMar PharmaMar PharmaMar
P1-233: Efficacy of carboplatin (C ) and etoposide (E ) for extensive stage small cell lung cancer (ED-SCLC)
Authors: Ufuk Yilmaz, Huseyin Halilcolar, Sena Yapicioglu, Yasemin Yildirim, Ipek Unsal, Ceyda Mahlec
Journal: Journal of Thoracic Oncology (2007)
Targeting tyrosine receptor kinase B in gliomas
Authors: Kelly V. Pinheiro, Camila Alves, Marienela Buendia, Mirela S. Gil, Amanda Thomaz, Gilberto Schwartsmann, Caroline Brunetto de Farias, Rafael Roesler, Robert L. Bowman, Qianghu Wang, Angel Carro, Roel G.W. Verhaak, Massimo Squatrito
Journal: Neuro-Oncology (2016)
Responses to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF in Ph1-positive acute lymphoblastic leukemia with myeloid surface markers [letter] [see comments]
Authors: H Tsuchiya, N Adachi, N Asou, K Takatsuki, I Matsuda, F Kawano, T Murakami, S Mizutani, M Watanabe
Journal: Blood (1991)
Skin Cancer Risk Reduction Behaviors Among American Indian and Non-Hispanic White Persons in Rural New Mexico
Authors: Mary E. Logue, Tyler Hough, Yuridia Leyva, Jaron Kee, Marianne Berwick
Journal: JAMA Dermatology (2016)

Audrey A. Jacobsen, BA; Ana Galvan, BS; Claudina Canaan Lachapelle, MD; Cheryl B. Wohl, MPH; Robert S. Kirsner, MD, PhD; John Strasswimmer, MD, PhD
v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1
Authors: Xiaoming Ju, Xuanmao Jiao, Adam Ertel, Mathew C. Casimiro, Gabriele Di Sante, Shengqiong Deng, Zhiping Li, Agnese Di Rocco, Tingting Zhan, Adam Hawkins, Tanya Stoyanova, Sebastiano Andò, Alessandro Fatatis, Michael P. Lisanti, Leonard G. Gomella, Lucia R. Languino, Richard G. Pestell
Journal: Cancer Research (2016)

Proteomic analysis of castration-resistant prostate cancer demonstrated the enrichment of Src tyrosine kinase activity in approximately 90% of patients. Src is known to induce cyclin D1, and a cyclin D1-regulated gene expression module predicts poor outcome in human prostate cancer. The tumor-associated calcium signal transducer 2 (TACSTD2/Trop2/M1S1) is enriched in the prostate, promoting prostate stem cell self-renewal upon proteolytic activation via a γ-secretase cleavage complex (PS1, PS2) and TACE (ADAM17), which releases the Trop2 intracellular domain (Trop2 ICD). Herein, v-Src transformation of primary murine prostate epithelial cells increased the proportion of prostate cancer stem cells as characterized by gene expression, epitope characteristics, and prostatosphere formation. Cyclin D1 was induced by v-Src, and Src kinase induction of Trop2 ICD nuclear accumulation required cyclin D1. Cyclin D1 induced abundance of the Trop2 proteolytic cleavage activation components (PS2, TACE) and restrained expression of the inhibitory component of the Trop2 proteolytic complex (Numb). Patients with prostate cancer with increased nuclear Trop2 ICD and cyclin D1, and reduced Numb, had reduced recurrence-free survival probability (HR = 4.35). Cyclin D1, therefore, serves as a transducer of v-Src-mediated induction of Trop2 ICD by enhancing abundance of the Trop2 proteolytic activation complex. Cancer Res; 76(22); 6723-34. ©2016 AACR.
Ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertension: a cardiac magnetic resonance study
Authors: T. M. Gorter, E. A. M. Verschuuren, D. J. Van Veldhuisen, E. S. Hoendermis, M. E. Erasmus, H. J. Bogaard, A. Vonk Noordegraaf, R. M. F. Berger, J. P. Van Melle, T. P. Willems
Journal: European Journal of Heart Failure (2016)
Evaluation of variants of the rs1934951 locus of <i>CYP2C8</i> and bisphosphonate-related osteonecrosis of the jaw in castrate-resistant prostate cancer (CRPC) patients.
Authors: P. G. Kluetz, B. C. English, C. E. Baum, T. M. Sissung, D. Adelberg, W. L. Dahut, D. K. Price, W. D. Figg
Journal: Journal of Clinical Oncology (2010)

9076 Background: Bisphosphonates (BPs) have been shown to prevent or delay skeletal events in patients with bone metastases. The FDA has approved IV zoledronic acid for men with bone metastases from prostate cancer who are failing hormonal therapy. Unfortunately, BPs have been associated with osteonecrosis of the jaw (ONJ). A recent study reported an association between an intronic SNP in CYP2C8 and the development of ONJ in multiple myeloma patients treated with BPs. Our group evaluated the same SNP to determine if there was an association with development of ONJ in men with prostate cancer treated with BPs Methods: 100 men with CRPC treated with BPs for bone metastases were randomly selected from several chemotherapy-based trials conducted at the National Cancer Institute. These patients were retrospectively genotyped via direct sequencing at the CYP2C8 locus (rs1934951) using nested PCR. DNA was extracted from plasma using a QIAamp UltraSens Virus Kit (Qiagen) and stored at 4°C. Statistical analysis was performed with NCSS 2004 software using Chi-squared, Fisher's exact test, and analysis of variance. Patient records were reviewed for type and duration of BP use as well as development of ONJ. We categorized the patients into two groups: those who received BP therapy for less than one year versus those for greater or equal to one year. Results: All patients received BP, chemotherapy, steroids, and antiangiogenic therapy. 78% of patients were treated with BP for over one year. 17 patients (17%) developed ONJ. There was no statistically significant association between the variant allele and development of ONJ (OR = 0.63, 95%CI = 0.17-2.42, P>0.46). All genotypes were found to be in Hardy-Weinberg equilibrium. Of the 3 homozygous variant men, none developed ONJ, although this was not statistically significant. Race, age at prostate cancer diagnosis, and type and duration of BP treatment were consistent between those who developed ONJ and those who did not (P>0.05). Conclusions: We found no significant association between the previously reported CYP2C8 SNP and incidence of BP-associated ONJ in a cohort of 100 prostate cancer patients. No significant financial relationships to disclose.
P1-107: Evaluation of Simian Virus-40 as a biological prognostic factor in egyptian patients with malignant pleural mesothelioma
Authors: Abeer A. Bahnassy, Rabab M. Gaafar, Abdel-Rahman N. Zekri, Waleed S. Mohamed, Nelly A. Hassan, Mohamed Abdel-Rahman, Fatma Abou-El-Kassem
Journal: Journal of Thoracic Oncology (2007)
What Would a Republican Win Mean for Health Policy?
Authors: Gail R. Wilensky
Journal: New England Journal of Medicine (2016)

Interview with Dr. Paul Ginsburg on what the 2016 election will mean for health care reform. (10:16)Download Donald Trump supports some common GOP proposals, such as expanding the availability of health savings accounts and turning Medicaid into block grants. But if the election results in a split Congress, will Republicans be willing to work to “fix” the Affordable Care Act?
Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing
Authors: Todd A Fehniger, Kilannin Krysiak, Brian S White, Matthew Matlock, Chris Miller, Robert Fulton, Friederike Kreisel, Catrina Fronick, Lisa Cook, Joelle Veizer, Amanda F. Cashen, Kenneth R Carson, Melissa M Berrien-Elliott, Nancy L Bartlett, Richard K Wilson, Elaine R Mardis, Timothy J Ley, Malachi Griffith, Obi L Griffith
Journal: Blood (2015)
Biological Significance and Profile of Length Heteroplasmy in the Hypervariable Segments of the Human Mitochondrial DNA Control Regions from Blood Cells.
Authors: Myung-Geun Shin, Hyeoung-Joon Kim, Hye-Ran Kim, Hee-Nam Kim, Il-Kwon Lee, Hoon Kook, Duck Cho, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang
Journal: Blood (2004)
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
Authors: Jean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, Eric Vallières, Bartosz Kubisa, Eugeny Levchenko, Sebastian Wiesemann, Gregory A. Masters, Robert Shen, Sergei A. Tjulandin, Hans-Stefan Hofmann, Nicolas Vanhoutte, Bruno Salaun, Muriel Debois, Silvija Jarnjak, Pedro Miguel De Sousa Alves, Jamila Louahed, Vincent G. Brichard, Frédéric F. Lehmann
Journal: Journal of Thoracic Oncology (2016)

IntroductionAdjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially expressed antigen of melanoma (PRAME) tumor antigen is expressed in two-thirds of NSCLC and offers an attractive target for antigen-specific immunization. A phase I dose escalation study assessed the safety and immunogenicity of a PRAME immunotherapeutic consisting of recombinant PRAME plus proprietary immunostimulant AS15 in patients with surgically resected NSCLC (NCT01159964).MethodsPatients with PRAME-positive resected stage IB to IIIA NSCLC were enrolled in three consecutive cohorts to receive up to 13 injections of PRAME immunotherapeutic (recombinant PRAME protein dose of 20 μg, 100 μg, or 500 μg, with a fixed dose of AS15). Adverse events, predefined dose-limiting toxicity, and the anti-PRAME humoral response (measured by enzyme-linked immunosorbent assay) were coprimary end points. Anti-PRAME cellular responses were assessed.ResultsA total of 60 patients were treated (18 received 20 μg of PRAME, 18 received 100 μg of PRAME, and 24 received 500 μg of PRAME). No dose-limiting toxicity was reported. Adverse events considered by the investigator to be causally related to treatment were grade 1 or 2, and most were injection site reactions or fever. All patients had detectable anti-PRAME antibodies after four immunizations. The percentages of patients with PRAME-specific CD4-positive T cells were higher at the dose of 500 μg compared with lower doses. No predefined CD8-positive T-cell responses were detected.ConclusionThe PRAME immunotherapeutic had an acceptable safety profile. All patients had anti-PRAME humoral responses that were not dose related, and 80% of those treated at the highest dose showed a cellular immune response. The dose of 500 μg was selected. However, further development was stopped after negative results with a similar immunotherapeutic in patients with NSCLC.
Molecular Evolution Patterns in Metastatic Lymph Nodes Reflect the Differential Treatment Response of Advanced Primary Lung Cancer
Authors: Sang-Won Um, Je-Gun Joung, Hyun Lee, Hojoong Kim, Kyu-Tae Kim, Jinha Park, D. Neil Hayes, Woong-Yang Park
Journal: Cancer Research (2016)

Tumor heterogeneity influences the clinical outcome of patients with cancer, and the diagnostic method to measure the tumor heterogeneity needs to be developed. We analyzed genomic features on pairs of primary and multiple metastatic lymph nodes from six patients with lung cancer using whole-exome sequencing and RNA sequencing. Although somatic single-nucleotide variants were shared in primary lung cancer and metastases, tumor evolution predicted by the pattern of genomic alterations was matched to anatomic location of the tumors. Four of six cases exhibited a branched clonal evolution pattern. Lymph nodes with acquired somatic variants demonstrated resistance to the cancer treatment. In this study, we demonstrated that multiple biopsies and sequencing strategies for different tumor regions are required for a comprehensive understanding of the landscape of genetic alteration and for guiding targeted therapy in advanced primary lung cancer. Cancer Res; 76(22); 6568-76. ©2016 AACR.
P0351 : Highly sensitive α-fetoprotein, Lens culinaris agglutinin-reactive fraction of α-fetoprotein and des-γ-carboxy prothrombin for hepatocellular carcinoma detection in an Italian cohort
Authors: M.L. Abate, G.P. Caviglia, E. Petrini, S. Gaia, P. Carucci, A. Smedile
Journal: Journal of Hepatology (2015)
C4-07: evaluation of radiofrequency ablation for thoracic malignancies using PDG-PET-CT scan
Authors: Hiroyuki Suzuki, Hiroshi Honjo, Suguru Ishida, Yutaka Shio, Mitsunori Higuchi, Mika Hoshino, Jun Ohsugi, Atsushi Yonechi, Takeo Hasegawa, Fumio Shishido, Mitsuru Munakata, Mitsukazu Gotoh
Journal: Journal of Thoracic Oncology (2007)
Glycosylation of a type 2 Factor VIII inhibitor determines its maximum level of Factor VIII inhibition
Authors: M. G. Jacquemin, Lavend apos, R. homme, L. Vanderelst, A. Benhida, J. Dewaele, K. Peerlinck, J. G. y Gilles, J. Vermylen, J. M. rie Saint Remy
Journal: Blood (2003)
The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive patients.
Authors: R. Yerushalmi, R. Woods, K. A. Gelmon, C. Speers, P. Ravdin
Journal: Journal of Clinical Oncology (2010)

539 Background: There is a strong evidence in the literature that Ki67 is prognostic for breast cancer-specific survival (BCSS). There are controversial studies regarding its predictive role for adjuvant hormone therapy. We examined whether Ki67 can predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive (ER+) patients. Methods: Patients with early-stage breast cancer who were diagnosed between 1986 and 1992 and referred to the British Columbia Cancer Agency were included in this study. All patients were ER (+), node negative, had T1/T2 tumors, and had not received adjuvant chemotherapy. Median follow-up was 12.4 years. Ki67 status was determined by immunohistochemistry using 10% cells staining as a cutoff value. Associations between whether tamoxifen was used as adjuvant chemotherapy, Ki67 status, and BCSS were assessed using Cox proportional-hazards models and Kaplan-Meier plots. Results: 710 patients met all criteria. Ki67 was a strong negative prognostic parameter (HR = 1.67, p = 0.01). Overall tamoxifen had no effect, HR = 0.92, p = 0.50. However, in the subset of patients who had a low Ki67, the patients who were treated with tamoxifen benefited, HR = 0.63, p = 0.08, while the subset with high Ki67 did not, HR=1.07, p = 0.65; test for interaction, p=0.01. Conclusions: Our study confirms Ki67's role as a prognostic marker. Moreover, low Ki67 predicted benefit from tamoxifen in the ER (+), node-negative patients. We report that low Ki67 expression was associated with a HR of 0.63 for tamoxifen. We estimate that if tamoxifen assignment had been based on randomization, an HR of about 0.70 would be expected based on the EBCTCG data. If future randomized studies using an accepted methodology and cutoff point for Ki67 find it comparable to more costly genetic tests, Ki67 may prove useful in predicting benefit from systemic adjuvant treatment in areas of the world where funding is a concern. BCSS at 10 years of follow-up for node-negative, ER (+) in patients not receiving adjuvant chemotherapy No tamoxifen Tamoxifen n BCSS s.e. BCSS s.e. All patients 210/710 0.918 0.011 0.892 0.022 Low Ki67 99/408 0.942 0.012 0.979 0.015 High Ki67 111/302 0.887 0.019 0.823 0.038 No significant financial relationships to disclose.
From Volume to Value in Health Care
Authors: Michael E. Porter, Thomas H. Lee
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P1-01-10: Comparison of sentinel lymph node positivity rates pre and post introduction of OSNA molecular analysis
Authors: J Rusby, E Agabiti, S Waheed, P Barry, N Roche, W Allum, G Gui, F MacNeill, G Christaki, P Osin, A Nerurkar
Journal: Cancer Research (2012)

Abstract Introduction: Intra-operative assessment (IOA) of the axillary sentinel lymph node (SLN) allows immediate completion axillary lymph node dissection (cALND) for a positive SLN. One-step nucleic acid amplification assay (OSNA, (Sysmex)), a molecular technique, is very sensitive and may upstage the axilla compared with other forms of intra-operative assessment and with formal, paraffin-embedded haematoxylin and eosin (H&amp;E) histopathology. This would result in an increased cALND rate at a time when efforts are being made to reduce unnecessary axillary surgery in line with the Z0011 trial (Giuliano et al. 2011). This study compares node positive rates before and after two changes in practice: the introduction of OSNA and the unit policy to perform cALND for macrometastatic SLN disease only. Methods: All patients in our unit undergo pre-operative axillary ultrasound with fine needle aspiration cytology of any suspicious nodes. Those with malignant cytology proceed directly to ALND. Radiologically and cytologically node negative patients undergo SLNB. Consecutive electronic records were examined for all SLNB procedures in two groups: Pre-OSNA from June 2006 to December 2010 and OSNA from August 2011 to March 2012. Pre-OSNA, patients were offered cALND for micro-or macroscopic SLN disease identified by H&amp;E histology. Following Z0011, patients in the OSNA group proceeded to cALND for SLN macrometastases but not for micrometastases. The chi-squared test was used to compare results between the two groups. Results: The groups were similar in terms of age, tumour size, grade and receptor status. Sentinel node and cALND results are shown in table 1. In summary, testing by OSNA resulted in a higher node positive rate and a greater proportion reported with micrometastases (40% compared with 23% pre-OSNA). The OSNA macrometastasis rate was equal to the pre-OSNA overall node positive rate (22%). Among patients proceeding to cALND (all node-positive pre-OSNA patients and OSNA patients with macrometastases) there was no significant difference in the proportion with additional positive nodes in the cALND or the proportion with a total of four or more positive nodes. Conclusion: The introduction of OSNA has increased the proportion of patients identified as node positive, and has increased the proportion reported to have macrometastasis. Simultaneously, the decision not to perform cALND for patients with micrometastasis was intended to limit the additional surgery performed in the SLNB group as a whole. However, since this decision was based on data from studies using H&amp;E assessment, we should look for ways to raise the threshold for cALND such that it includes only the patients at the highest risk of axillary recurrence. Reference Giuliano AE et al. JAMA 2011; 305(6): 569–75. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-10.
Genome-Wide Array-Based CGH for Mantle Cell Lymphoma: Precise Mapping of Genomic Aberrations and Identification of Novel Candidate Genes.
Authors: Hiroyuki Tagawa, Siversundram Karnan, Ritsuro Suzuki, Akinobu Ota, Shinobu Tsuzuki, Yasuo Morishima, Shigeo Nakamura, Masao Seto
Journal: Blood (2004)
P1-121: Accuracy of pleural biopsy by thoracoscopy for the diagnosis of histological subtype in malignant pleural mesothelioma
Authors: Laurent Greillier, Arnaud Cavailles, Anne Fraticelli, Arnaud Scherpereel, Fabrice Barlesi, Gian Franco Tassi, Pascal A. Thomas, Philippe Astoul
Journal: Journal of Thoracic Oncology (2007)